Windlas Biotech (NSE:WINDLAS) Other Stockholders Equity: ₹375 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
91 GF Score
Price ₹827.70
GF Value ₹942.26
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Other Stockholders Equity?

Windlas Biotech NSE:WINDLAS -3.07% 91 Other Stockholders Equity is ₹375 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 91/100 and a GF Value™ of ₹942.26 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Windlas Biotech's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹375 Mil.

Windlas Biotech's quarterly Other Stockholders Equity declined from Sep. 2025 (₹5,235 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹375 Mil).

Windlas Biotech's annual Other Stockholders Equity increased from Mar. 2024 (₹185 Mil) to Mar. 2025 (₹209 Mil) and increased from Mar. 2025 (₹209 Mil) to Mar. 2026 (₹375 Mil).

Windlas Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Other Stockholders Equity Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial 154.29 164.10 184.72 209.26 375.37

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.26 0.00 5,235.46 0.00 375.37
NSE:WINDLAS
91GF Score
Windlas Biotech Ltd NSE:WINDLAS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹375 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Other Stockholders Equity of ₹375 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Other Stockholders Equity too high?
Windlas Biotech's current Other Stockholders Equity is ₹375 Mil. Overall, Windlas Biotech has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Other Stockholders Equity compare to ZTS and UTHR?
Windlas Biotech's Other Stockholders Equity of ₹375 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Other Stockholders Equity is ₹375 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹942.26, compared to a current price of ₹827.70 — trading 12.2% below its estimated fair value. The current Other Stockholders Equity is ₹375 Mil. Windlas Biotech's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Other Stockholders Equity is ₹375 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹827.70 is trading 12.2% below its estimated GF Value™ of ₹942.26. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Other Stockholders Equity: ₹375 Mil
  • GF Value™: ₹942.26 vs. price of ₹827.70 (12.2% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
91GF Score

Get the complete analysis for NSE:WINDLAS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹827.70
Price
₹942.26
GF Value